Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | DHFR | P00374 | 1/20 | 0.30 |
| ▸ | HEXA | P06865 | 1/20 | 0.30 |
| ▸ | HEXB | P07686 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264598 | 0.81 | ADORA2A (0.33) | ADORA2A | |
| SCHEMBL2610983 | 0.72 | LIMK1 (0.40) | ADORA2ANOS3NOS1NOS2 | |
| SCHEMBL264417 | 0.67 | CYP1A2 (0.41) | — | |
| SCHEMBL15339503 | 0.67 | IDO1 (0.31) | IDO1 | |
| SCHEMBL24757554 | 0.67 | NUDT1 (0.37) | — | |
| SCHEMBL12559509 | 0.63 | CCR1 (0.38) | NOS3NOS1NOS2 | |
| SCHEMBL21983360 | 0.61 | KDM4E (0.43) | ADORA2AIDO1NOS3NOS1NOS2 | |
| SCHEMBL5040005 | 0.61 | ALDH2 (0.35) | — | |
| SCHEMBL7940046 | 0.61 | ADORA2A (0.48) | ADORA2ADHFR | |
| SCHEMBL19520099 | 0.60 | ADORA2A (0.48) | ADORA2ANOS3NOS1NOS2DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163703-B2 | Hepatitis C therapies | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8133870-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20100143300-A1 | HEPATITIS C THERAPIES | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-06-10 | — | — | US | disclosed |
| US-7514410-B2 | Hepatitis C therapies | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-7429571-B2 | Therapeutic furopyrimidines and thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | DPYD, TYMP, TYMS | ADORA2A 2082/4885IDO1 1823/4885NOS3 3286/4885 |
| US-20100143300-A1 | HEPATITIS C THERAPIES | HAVCR2, FABP1, LIPC | ADORA2A 1148/4885IDO1 1391/4885NOS3 575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.